MRNA vs PFE
Moderna, Inc. vs Pfizer Inc. · Updated Nov 13, 2026
MRNA — 6 winsPFE — 14 wins
Price Performance
MRNA +807.13%PFE +11.31%
Performance
| MRNA | PFE | |
|---|---|---|
| 1 Month | +2.72% | -0.87% |
| 3 Months | +267.10% | +8.08% |
| 6 Months | +364.61% | +12.45% |
| YTD | +688.22% | +16.29% |
| 1 Year | +780.14% | +13.50% |
| 3 Year | +215.56% | -15.04% |
| 5 Year | -18.16% | -21.68% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | +633.7% | -29.8% | -63.0% | -44.4% | -23.6% | +127.3% | +443.3% | +27.6% | -17.9% | — | — | — |
| PFE | +14.0% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
Valuation
| MRNA | PFE | |
|---|---|---|
| P/E Ratio | -6.55 | 22.10 |
| Forward P/E | — | 9.08 |
| PEG Ratio | 19.56 | -3.95 |
| P/S Ratio | 43.33 | 2.65 |
| P/B Ratio | 13.01 | 1.86 |
| EV/EBITDA | -42.55 | 13.77 |
Financials
| MRNA | PFE | |
|---|---|---|
| EPS (TTM) | $-8.15 | $1.31 |
| Gross Margin | -145.50% | +67.26% |
| Operating Margin | -356.81% | +27.90% |
| Net Margin | -345.24% | +18.60% |
| ROE | -43.12% | +8.31% |
| ROA | -27.80% | +3.61% |
| Debt/Equity | 0.18 | 0.72 |
Growth
| MRNA | PFE | |
|---|---|---|
| Revenue Growth YoY | +263.55% | +5.37% |
| Revenue Growth QoQ | -42.63% | -17.69% |
| EPS Growth YoY | -34.92% | -9.55% |
| EPS Growth QoQ | -61.14% | +262.07% |
Technical
| MRNA | PFE | |
|---|---|---|
| RSI (14) | 53.20 | 46.81 |
| % From 20-Day SMA | +0.97% | -2.92% |
| % From 50-Day SMA | +16.12% | +0.54% |
| % From 200-Day SMA | +143.32% | +7.36% |
| % From 52-Week High | -17.22% | -7.90% |
| % From 52-Week Low | +943.29% | +22.59% |
Analyst Ratings
MRNA
Hold(24 analysts)
Strong SellHoldStrong Buy
Price Target
$132.70
-49.08% upside
PFE
Hold(18 analysts)
Strong SellHoldStrong Buy
Price Target
$31.13
+6.46% upside
Overview
| MRNA | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Exchange | NASDAQ | NYSE |
| Market Cap | $96.40B | $167.86B |
| Shares Outstanding | 399.2M | 5.70B |
| Avg Volume (10D) | 10.79M | 43.32M |
| Dividend Yield | — | 5.84% |
Frequently Asked Questions
Is MRNA or PFE a better buy right now?
Based on 20 comparable metrics, PFE leads in 14 categories while MRNA leads in 6. PFE has a consensus analyst rating with 18 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, MRNA or PFE?
Over the past year, MRNA returned +780.14% compared to PFE's +13.50%. In the short term (1 month), MRNA returned +2.72% vs PFE's -0.87%.
Is MRNA or PFE more expensive?
MRNA trades at a P/E of -6.55 compared to PFE's 22.10. On a price-to-sales basis, MRNA trades at 43.33x vs PFE's 2.65x. Forward P/E: MRNA at — vs PFE at 9.08.
Which stock has higher growth, MRNA or PFE?
MRNA's revenue grew +263.55% year-over-year compared to PFE's +5.37%. EPS growth: MRNA at -34.92% vs PFE at -9.55%.
Do MRNA and PFE pay dividends?
MRNA does not currently pay a dividend. PFE pays a dividend with a yield of 5.84%.
Which stock do analysts prefer, MRNA or PFE?
MRNA has 24 analysts with a target price of $132.70 (-49.08% upside). PFE has 18 analysts with a target of $31.13 (+6.46% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.